PATENT CLAIM ANALYSIS

Application Number: 16326272
Application Type: Utility
Filing Date: 2019-02
Publication Date: 2019-06
Patent Classification: ["514", "653000"]

Abstract:
Provided are methods of and compositions for treating or preventing lymphedema by administering a sphingosine 1-phoshate receptor modulator.

Claim (Index 2):
The method of  claim 1 , wherein the S1P receptor inhibitor is selected from the group consisting of FTY720 (Fingolimod), ONO-4641 (Ceralifimod), RPC1063 (Ozanimod), ACT-128800 (Ponesimod), BAF312 (Siponimod), LT1009 (Sonepcizumab), AAL-R ((R)-2-amino-4-(4-heptyloxyphenyl)-2-methylbutanol), CS-0777 ((R)-1-(5-(3-amino-4-hydroxy-3-methylbutyl)-1-methyl-1H-pyrrol-2-yl)-4-(p-tolyl)butan-1-one), KRP-203 (2-amino-2-propanediol), RP-001 (N-[4-[5-[3-Cyano-4-(1-methylethoxy)phenyl]-1,2,4-oxadiazol-3-yl]-2,3-dihydro-1H-iden-1-yl]-\u03b2-alanine), and Syl930.

Metadata:
- Claim Count in Document: 50.0
- Percentile: 99.0
- Lexical Diversity: 1.0
- Patent Class: 514.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['15549156', '15554931', '13136372', '15389509', '15114572']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.8000311289837984
- 35 USC 102 Novelty (BERT): 0.5577427319838033
- Combined Prediction Score: 0.7758022892837989
- Mean Citation Score: 304.6740000000001
- Max Citation Score: 461.55603
- Similarity Product: 317.9523558735788

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test